

Supporting Information

Transition-Metal-Free Regioselective C-H Halogenation of Imidazo[1,2-*a*]pyridines: Sodium Chlorite/Bromite as the Halogen Source

Junxuan Li,^a Jiayi Tang,^a Yuanheng Wu,^a Qiuxing He,^{a*} and Yue Yu^{a*}

^a School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, P. R. China.

E-mail: yuyue@gdpu.edu.cn; heqiuxing@126.com

Fax: +86 (760) 88207939

| | |
|--|-----|
| 1. General consideration..... | II |
| 2. General procedure..... | II |
| 3. Characterization data..... | III |
| 4. ¹ H and ¹³ C NMR spectra..... | XI |

1. General consideration


¹H and ¹³C NMR spectra were recorded at 400 and 100 Hz, respectively. Mass spectra were recorded were obtained on a ESIMS. Elemental analyses were performed with a elemental analyzer. GC-MS was obtained using electron ionization. TLC was performed using commercially prepared 100-400 mesh silica gel plates.

2. General procedure

Synthesis of 2a according to the following procedure: A 25 mL sealed tube was charged with a stirring bar, and added imidazo[1,2-*a*]pyridine **1a** (0.5 mmol, 1.0 equiv), NaClO₂ (1 mmol, 2.0 equiv), AcOH (2 mmol) and DMF (2 mL). The reaction was allowed to stir at 60°C until the complete consumption of **2a** was monitored by TLC analysis. The reaction mixture was purified by thin layer chromatography silica gel plate (eluent: petroleum ether : ethyl acetate, V : V = 10 : 1) and then extracted with EtOAc. The solvents were dried in vacuo to afford the pure product.


3. Characterization data

2a 3-Chloroimidazo[1,2-*a*]pyridine




Brown oil (63.1 mg, 83%); IR (KBr): 2992, 1486, 1219, 1037, 954 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, *J* = 6.4 Hz, 1H), 7.61 (t, *J* = 9.2 Hz, 2H), 7.21 (t, *J* = 7.6 Hz, 1H), 6.91 (t, *J* = 6.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 144.7, 130.2, 124.2, 122.5, 118.0, 112.9, 109.6. ESI-MS m/z (%) 153(100)[M+H]⁺; Anal. Calcd for C₇H₅ClN₂ C, 55.10; H, 3.30; N, 18.36; Found: C, 54.91; H, 3.31; N, 18.45.

2b 3-Chloro-6-methylimidazo[1,2-*a*]pyridine




Brown oil (66.4 mg, 80%); IR (KBr): 2986, 1476, 1233, 1025, 960 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.52 (d, *J* = 6.0 Hz, 2H), 7.08 (d, *J* = 9.2 Hz, 1H), 2.38 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 143.6, 129.9, 127.5, 122.8, 120.2, 117.4, 109.2, 18.3. ESI-MS m/z (%) 167(100)[M+H]⁺; Anal. Calcd for C₈H₇ClN₂ C, 57.67; H, 4.24; N, 16.81; Found: C, 57.43; H, 4.23; N, 16.89.

2c 3,6-Dichloroimidazo[1,2-*a*]pyridine




Yellow oil (62.3 mg, 67%); IR (KBr): 2989, 1506, 1249, 899, 690 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.13 (s, 1H), 7.57 (d, *J* = 9.6 Hz, 2H), 7.19 (d, *J* = 8.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 131.0, 126.0, 126.0, 121.8, 120.7, 118.5, 100.0. ESI-MS m/z (%) 187(100)[M+H]⁺; Anal. Calcd for C₇H₄Cl₂N₂ C, 44.95; H, 2.16; N, 14.98; Found: C, 45.09; H, 2.13; N, 14.90.

2d 3-Chloro-6-iodoimidazo[1,2-*a*]pyridine




Brown oil (88.6 mg, 64%); IR (KBr): 2977, 1456, 1228, 1027, 954 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.31 (s, 1H), 7.51 (s, 1H), 7.44-7.33 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 143.0, 132.5, 130.4, 127.7, 118.9, 118.9, 109.5. ESI-MS m/z (%) 278(100)[M+H]⁺; Anal. Calcd for C₇H₄ClIN₂ C, 30.19; H, 1.45; N, 10.06; Found: C, 30.47; H, 1.40; N, 9.95.

2e 3-Chloro-7-methylimidazo[1,2-a]pyridine




Brown oil (70.1 mg, 85%); IR (KBr): 2973, 1478, 1259, 1011, 931 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 6.8 Hz, 1H), 7.47 (s, 1H), 7.36 (s, 1H), 6.76 (d, *J* = 7.2 Hz, 1H), 2.41 (s, 3H). ¹³C NMR (100MHz, CDCl₃) δ 144.8, 135.5, 129.6, 121.7, 116.3, 115.7, 109.0, 21.2. ESI-MS m/z (%) 167(100)[M+H]⁺; Anal. Calcd for C₈H₇ClN₂ C, 57.67; H, 4.24; N, 16.81; Found: C, 57.45; H, 4.26; N, 16.89.

2f 3-Chloro-8-methylimidazo[1,2-a]pyridine




Brown oil (73.8 mg, 89%); IR (KBr): 2956, 1485, 1237, 1017, 921 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, *J* = 6.8 Hz, 1H), 7.46 (s, 1H), 6.94 (d, *J* = 6.8 Hz, 1H), 6.78 (t, *J* = 6.8 Hz, 1H), 2.53 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.8, 129.4, 127.9, 123.2, 120.5, 113.1, 109.9, 16.4. ESI-MS m/z (%) 167(100)[M+H]⁺; Anal. Calcd for C₈H₇ClN₂ C, 57.67; H, 4.24; N, 16.81; Found: C, 57.41; H, 4.22; N, 16.90.

2g 3-Chloro-2-methylimidazo[1,2-a]pyridine




Yellow oil (66.4 mg, 80%); IR (KBr): 2899, 1453, 1172, 1023, 857 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, *J* = 6.8 Hz, 1H), 7.54 (d, *J* = 8.8 Hz, 1H), 7.20 (t, *J* = 8.0 Hz, 1H), 6.90 (t, *J* = 6.8 Hz, 1H), 2.46 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 143.3, 138.8, 124.1, 122.4, 117.0, 112.5, 110.2, 12.8. ESI-MS m/z (%) 167(100)[M+H]⁺; Anal. Calcd for C₈H₇ClN₂ C, 57.67; H, 4.24; N, 16.81; Found: C, 57.87; H, 4.21; N, 16.72.

2h 3-Chloro-2,6-dimethylimidazo[1,2-*a*]pyridine




Yellow oil (72.9 mg, 81%); IR (KBr): 2907, 1444, 1208, 1021, 869 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (s, 1H), 7.32 (d, *J* = 9.2 Hz, 1H), 6.93 (d, *J* = 9.2 Hz, 1H), 2.34 (s, 3H), 2.25 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 142.4, 138.5, 127.1, 122.1, 120.1, 116.2, 105.9, 18.2, 12.8. ESI-MS m/z (%) 181(100)[M+H]⁺; Anal. Calcd for C₉H₉ClN₂ C, 59.84; H, 5.02; N, 15.51; Found: C, 60.03; H, 4.99; N, 15.43.

2i 3-Chloro-2,7-dimethylimidazo[1,2-*a*]pyridine



Yellow oil (72.9 mg, 81%); IR (KBr): 2906, 1515, 1230, 1008, 906 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.77 (t, *J* = 6.8 Hz, 1H), 7.17 (s, 1H), 6.62-6.58 (m, 1H), 2.34-2.30 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 143.7, 138.2, 135.1, 121.6, 115.4, 115.0, 105.7, 21.2, 12.7. ESI-MS m/z (%) 181(100)[M+H]⁺; Anal. Calcd for C₉H₉ClN₂ C, 59.84; H, 5.02; N, 15.51; Found: C, 59.59; H, 5.04; N, 15.58.


2j 3-Chloro-2,8-dimethylimidazo[1,2-*a*]pyridine



Brown oil (70.2 mg, 78%); IR (KBr): 2886, 1446, 1219, 1033, 846 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 6.8 Hz, 1H), 6.93 (d, *J* = 6.4 Hz, 1H), 6.75 (t, *J* = 6.8 Hz, 1H), 2.52 (s, 3H),


2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 143.6, 138.0, 126.8, 123.2, 120.4, 112.5, 108.7, 16.6, 12.8. ESI-MS m/z (%) 181(100)[M+H] $^+$; Anal. Calcd for $\text{C}_9\text{H}_9\text{ClN}_2$ C, 59.84; H, 5.02; N, 15.51; Found: C, 59.56; H, 5.05; N, 15.59.

2k 2-(*tert*-Butyl)-3-chloroimidazo[1,2-*a*]pyridine




Brown oil (89.4 mg, 86%); IR (KBr): 2957, 1476, 1239, 1037, 767 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, $J = 6.8$ Hz, 1H), 7.47 (d, $J = 8.8$ Hz, 1H), 7.04 (t, $J = 7.2$ Hz, 1H), 6.73 (t, $J = 6.8$ Hz, 1H), 1.39 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 149.5, 142.2, 123.6, 122.0, 117.2, 112.3, 104.3, 32.9, 29.6. ESI-MS m/z (%) 209(100)[M+H] $^+$; Anal. Calcd for $\text{C}_{11}\text{H}_{13}\text{ClN}_2$ C, 63.31; H, 6.28; N, 13.42; Found: C, 63.02; H, 6.31; N, 13.49.

2l 2-(*tert*-Butyl)-3-chloro-7-methylimidazo[1,2-*a*]pyridine



Brown oil (98.8 mg, 89%); IR (KBr): 2985, 1456, 1189, 10237, 860 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, $J = 7.2$ Hz, 1H), 7.25 (s, 1H), 6.61 (d, $J = 6.8$ Hz, 1H), 2.30 (s, 3H), 1.40 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 149.1, 142.7, 134.8, 121.3, 115.8, 115.0, 103.6, 32.9, 29.6, 21.2. ESI-MS m/z (%) 223(100)[M+H] $^+$; Anal. Calcd for $\text{C}_{12}\text{H}_{15}\text{ClN}_2$ C, 64.72; H, 6.79; N, 12.58; Found: C, 64.47; H, 6.77; N, 12.65.


2m 2-(*tert*-Butyl)-3-chloro-8-methylimidazo[1,2-*a*]pyridine



Brown oil (102.1 mg, 92%); IR (KBr): 2989, 1470, 1139, 1033, 861 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.88 (d, $J = 6.8$ Hz, 1H), 6.93 (d, $J = 6.8$ Hz, 1H), 6.76 (t, $J = 6.8$ Hz, 1H), 2.58 (s, 3H), 1.50 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 148.9, 142.5, 127.3, 122.4, 119.9, 112.3, 104.5, 33.0,


29.7, 16.5. ESI-MS m/z (%) 223(100)[M+H]⁺; Anal. Calcd for C₁₂H₁₅ClN₂ C, 64.72; H, 6.79; N, 12.58; Found: C, 64.52; H, 6.82; N, 12.64.

2n 2-(*tert*-Butyl)-3-chloro-6-methylimidazo[1,2-*a*]pyridine




Brown oil (96.6 mg, 87%); IR (KBr): 2899, 1516, 1228, 1066, 790 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.49 (d, *J* = 9.2 Hz, 1H), 7.02 (d, *J* = 9.2 Hz, 1H), 2.34 (s, 3H), 1.49 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 149.3, 141.3, 126.9, 122.2, 119.8, 116.6, 103.9, 32.90, 29.6, 18.3. ESI-MS m/z (%) 223(100)[M+H]⁺; Anal. Calcd for C₁₂H₁₅ClN₂ C, 64.72; H, 6.79; N, 12.58; Found: C, 64.44; H, 6.83; N, 12.65.

2o 3-Chloro-6-methyl-2-phenylimidazo[1,2-*a*]pyridine



Brown oil (94.4 mg, 78%); IR (KBr): 2913, 1496, 1230, 1041, 832 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 7.2 Hz, 2H), 7.87 (s, 1H), 7.54-7.45 (m, 3H), 7.36 (t, *J* = 7.2 Hz, 1H), 7.07 (d, *J* = 8.8 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 142.7, 139.4, 132.6, 128.4, 128.4, 128.0, 127.3, 122.7, 120.3, 116.8, 105.2, 18.3. ESI-MS m/z (%) 243(100)[M+H]⁺; Anal. Calcd for C₁₄H₁₁ClN₂ C, 69.28; H, 4.57; N, 11.54; Found: C, 68.99; H, 4.59; N, 11.60.

2p 6-Bromo-3-chloro-2-phenylimidazo[1,2-*a*]pyridine




Brown solid (104.0 mg, 68%), mp 142.8-145.4 °C; IR (KBr): 2933, 1436, 1175, 1028, 913 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.25-8.21 (m, 2H), 7.62-7.50 (m, 4H), 7.30-7.26 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 134.3, 130.1, 128.0, 127.8, 127.8, 123.9, 122.7, 118.6, 118.5, 108.1, 108.0. ESI-MS m/z (%) 307(100)[M+H]⁺; Anal. Calcd for C₁₃H₈BrClN₂ C, 50.76; H, 2.62; N, 9.11; Found: C, 51.02; H, 2.58; N, 9.07.

3a 3-Bromo-8-methylimidazo[1,2-*a*]pyridine




Brown oil (83.0 mg, 79%); IR (KBr): 2929, 1566, 880, 767, 682 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, *J* = 6.8 Hz, 1H), 7.59 (s, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.83 (t, *J* = 6.8 Hz, 1H), 2.60 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 146.1, 132.8, 127.7, 123.3, 121.6, 113.1, 95.0, 16.4. ESI-MS m/z (%) 211(100)[M+H]⁺; Anal. Calcd for C₈H₇BrN₂ C, 45.53; H, 3.34; N, 13.27; Found: C, 45.60; H, 3.35; N, 13.21.

3b 3-Bromo-6-methylimidazo[1,2-*a*]pyridine




Brown oil (73.5 mg, 70%); IR (KBr): 2929, 1588, 1466, 1251, 1031, 765 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.56 (s, 1H), 7.51 (d, *J* = 9.2 Hz, 1H), 7.07 (d, *J* = 9.2 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.9, 133.3, 127.7, 122.9, 121.4, 117.2, 94.2, 18.3. ESI-MS m/z (%) 211(100)[M+H]⁺; Anal. Calcd for C₈H₇BrN₂ C, 45.53; H, 3.34; N, 13.27; Found: C, 45.37; H, 3.35; N, 13.33.

3c 3-Bromo-7-methylimidazo[1,2-*a*]pyridine




Brown oil (75.6 mg, 72%); IR (KBr): 2913, 1579, 1416, 1040, 766 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, *J* = 6.8 Hz, 1H), 7.55 (s, 1H), 7.37 (s, 1H), 6.76 (d, *J* = 6.8 Hz, 1H), 2.42 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.0, 135.6, 133.2, 122.9, 116.3, 115.8, 93.8, 21.2. ESI-MS m/z (%) 211(100)[M+H]⁺; Anal. Calcd for C₈H₇BrN₂ C, 45.53; H, 3.34; N, 13.27; Found: C, 45.32; H, 3.32; N, 13.34.

3d 3-Bromo-2-methylimidazo[1,2-*a*]pyridine




Brown oil (74.6 mg, 71%); IR (KBr): 2988, 1473, 1139, 1009, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, *J* = 6.8 Hz, 1H), 7.52 (d, *J* = 9.2 Hz, 1H), 7.20 (t, *J* = 7.2 Hz, 1H), 6.88 (t, *J* = 6.8 Hz, 1H), 2.46 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 145.1, 141.8, 124.3, 123.6, 116.9, 112.6, 92.9, 13.6. ESI-MS m/z (%) 211(100)[M+H]⁺; Anal. Calcd for C₈H₇BrN₂ C, 45.53; H, 3.34; N, 13.27; Found: C, 45.61; H, 3.33; N, 13.21.

3e 3-Bromo-2-phenylimidazo[1,2-*a*]pyridine




Brown oil (112.9 mg, 83%); IR (KBr): 2976, 1573, 1432, 1072, 897, 782 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.11 (m, 3H), 7.64 (d, *J* = 9.2 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 2H), 7.39 (t, *J* = 7.2 Hz, 1H), 7.26-7.19 (m, 1H), 6.91 (t, *J* = 6.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 145.5, 142.7, 132.8, 128.5, 128.3, 127.9, 125.2, 124.0, 117.6, 113.1, 91.8. ESI-MS m/z (%) 273 (100)[M+H]⁺; Anal. Calcd for C₁₇H₉BrN₂ C, 57.17; H, 3.32; N, 10.26; Found: C, 56.38; H, 3.30; N, 10.21.

3f 3-Bromo-2-(*tert*-butyl)imidazo[1,2-*a*]pyridine




Brown oil (110.9 mg, 88%); IR (KBr): 2956, 1533, 1019, 884, 752 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, *J* = 4.8 Hz, 1H), 7.54 (d, *J* = 10.0 Hz, 1H), 7.13 (t, *J* = 8.0 Hz, 1H), 6.85-6.78 (m, 1H), 1.49 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 151.9, 143.7, 124.0, 123.2, 117.2, 112.5, 90.0, 33.0, 29.6. ESI-MS m/z (%) 253 (100)[M+H]⁺; Anal. Calcd for C₁₁H₁₃BrN₂ C, 52.19; H, 5.18; N, 11.07; Found: C, 51.96; H, 5.20; N, 11.13.

5a 3-(3,5-Dimethylphenyl)imidazo[1,2-*a*]pyridine



Yellow oil (49.3 mg, 74%); IR (KBr): 3006, 1461, 1010, 885, 709 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.32 (d, *J* = 6.9 Hz, 1H), 7.66 (t, *J* = 9.0 Hz, 2H), 7.18-7.14 (m, 3H), 7.05 (s, 1H), 6.78 (t, *J* = 6.8 Hz, 1H), 2.38 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 145.9, 138.7, 132.1, 131.9, 129.8, 128.9, 125.6, 123.9, 123.4, 118.0, 112.3, 21.2. ESI-MS m/z (%) 223 (100)[M+H]⁺; Anal. Calcd for C₁₅H₁₄N₂ C, 81.05; H, 6.35; N, 12.60; Found: C, 81.37; H, 6.25; N, 12.38.






6a 2-Methyl-3-(*o*-tolyl)imidazo[1,2-*a*]pyridine




Yellow oil (52.6 mg, 79%); IR (KBr): 3024, 1437, 1109, 894, 766 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.59-7.54 (m, 2H), 7.45-7.21 (m, 4H), 7.19-7.03 (m, 1H), 6.68 (t, *J* = 6.7 Hz, 1H), 2.34 (s, 3H), 2.06 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.3, 140.8, 138.9, 131.6, 130.6, 129.2, 129.1, 128.3, 126.3, 123.8, 123.3, 116.7, 111.7, 19.3, 13.6. ESI-MS m/z (%) 223 (100)[M+H]⁺; Anal. Calcd for C₁₅H₁₄N₂ C, 81.05; H, 6.35; N, 12.60; Found: C, 81.33; H, 6.27; N, 12.40.

4. ^1H and ^{13}C NMR spectra

2a







2b





2c


-8.13
7.58
7.56
7.26
7.20
7.18




2d




2e





2f




2g




2h



2i




2j





XX

2k




21





XXII

2m







2n







2p


8.25
8.21
7.62
7.57
7.52
7.50
7.30
7.29
7.27
7.26
7.26




3a




3b



3c




3d





XXX


3e



3f



5a



6a

